Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Journal of NeurochemistryOpen Access

Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain‐Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMaciej DulewiczJHJörg Hanrieder

Discussion

Loading...

Member takes

Overview

Assessment demonstrates elevated plasma tau biomarkers in Alzheimer's disease, indicating strong diagnostic potential.

Key Points

  • Plasma biomarkers for Alzheimer's disease were significantly elevated in both Possible and Probable AD groups compared to Controls.
  • The phosphorylated tau marker p-tau217 showed the highest diagnostic accuracy with an AUC of 0.954.
  • Assessment utilized Single Molecule Array assays for measuring tau and other neurodegenerative markers.
  • The findings support p-tau217's use as a screening tool for AD, although confirmatory testing is suggested due to moderate predictive value.

Cite This Study

Dulewicz et al. (2025) studied this question.

synapsesocial.com/papers/6930dc92ea1aef094cca2929https://doi.org/10.1111/jnc.70313
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1pROC: an open-source package for R and S+ to analyze and compare ROC curves2011 · 14,570 citations